Benzinga | Oct 16, 2020 12:06PM EDT

Maxim Group Initiates Coverage On Plus Therapeutics with Buy Rating, Announces Price Target of $6

Maxim Group analyst Jason McCarthy initiates coverage on Plus Therapeutics (NASDAQ:PSTV) with a Buy rating and announces Price Target of $6.